Prediction Case File
YouTubeEvaluation Complete

ZEC PRICE PREDICTION 2025

1 extracted signal · 1 resolved · 0 still active

Cilinix Crypto profile imageCilinix Crypto28 Nov 2025, 15:18 UTC
Video preview for ZEC PRICE PREDICTION 2025
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
1
Canonical correct result
Failed
0
Canonical failed result
Resolved success
100%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on ZECUSDT. Over the past week, the price has dropped 30%. Funding rates are negative. Technical breakdown on higher time frames has occurred. ZEC is still tradeable and reactive to technical support/resistance. Price action since November 7th indicates distribution. Daily time frame trend is lost, distribution is occurring. Target price is $300, strong support at $420. It is expected to push down to $420. It is possible that can see a spike until $515, where we have the monthly point of control. Then, push down until $420.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

Cilinix Crypto

Tracked signals
1195
Historical success
42.8%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.